



# NAME OF THE MEDICINAL PRODUCT

VISIPAQUE 270 mg I/ml, 320 mg I/ml

# **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Active ingredient	Strength	Content pr. ml.
lodixanol (INN) lodixanol (INN)	270 mg l/ml 320 mg l/ml	550 mg equiv. 270 mg l 652 mg equiv. 320 mg l

lodixanol is a non-ionic, dimeric, hexaiodinated, water-soluble X-ray

Pure aqueous solutions of iodixanol in all clinical relevant concentrations have a lower osmolality than whole blood and the corresponding strengths of the non-ionic monomeric contrast media. VISIPAQUE is made isotonic with normal body fluids by addition of electrolytes. The osmolality and viscosity values of VISIPAQUE are as follows:

Osmolality* mOsm/ka H.O	Viscosity (mPa•s)	
37°C	20°C 37°C	
290	11.3 5.8	
290	25.4 11.4	
	mOsm/kg Ĥ₂O 37°C 290	

\*Method: Vapour - pressure osmometry.

# PHARMACEUTICAL FORM

Solution for injection for intravenous and intra-arterial use. VISIPAQUE injections are supplied ready to use as clear, colourless to pale yellow aqueous solutions.

# **CLINICAL PARTICULARS**

#### Indications

X-ray contrast medium for use in adults for cardioangiography, cerebral angiography (conventional and i.a.DSA), peripheral arteriography (conventional and i.a.DSA), abdominal angiography (i.a.DSA), urography, venography and CT-enhancement.

# Posology and method of administration

The dosage may vary depending on the type of examination, the age, weight, cardiac output and general condition of the patient and the technique used. Usually approximately the same iodine concentration and volume is used as with other iodinated X-ray contrast media in current use, but adequate diagnostic information has also been obtained in some studies with iodixanol injection with somewhat lower iodine concentration. Adequate hydration should be assured before and after administration as for other contrast media.

Indication/Investigation

The following recommendations for an average dose for a normal adult may serve as a guide. The doses given for intra-arterial use are for single injections that may be repeated.

Concentration

Volume

Intra-arterial use		
Arteriographies		
selective cerebral	270/320 <sup>(1)</sup> mg I/ml	5-10 ml per inj.
aortography	270/320 mg l/ml	40-60 ml per inj.

peripheral selective visceral i.a.DSA	270/320 mg I/ml 270 mg I/ml	30-60 ml per inj. 10-40 ml per inj.
Cardioangiography Left ventricle and aortic root ini.	320 mg I/ml	30-60 ml per inj.
Selective coronary arteriography	320 mg I/ml	4-8 ml per inj.
ntravenous use		
Irography	270/320 mg I/ml	40-80 ml(2)
enography	270 mg I/ml	50-150 ml/leg
T-enhancement CT of the head CT of the body	270/320 mg l/ml 270/320 mg l/ml	50-150 ml 75-150 ml

- <sup>(1)</sup> Both strengths are documented, but 270 mg I/ml is recommended in most cases.
- <sup>(2)</sup> In high-dose urography higher doses can be used

# **Elderly**: As for other adults.

Children: Safety and efficacy in children has not yet been established.

#### Contra-indications

Manifest thyrotoxicosis. History of serious hypersensitivity reaction to VISIPAQUE.

# Special warnings and special precautions for use

Special precautions for use of non-ionic contrast media in general: A positive history of allergy, asthma, or untoward reactions to iodinated contrast media indicates a need for special caution. Premedication with corticosteroids or histamine  $H_1$  and  $H_2$  antagonists might be considered

The risk of serious reactions in connection with use of VISIPAQUE is regarded as very minor. However, iodinated contrast media may provoke serious or fatal reactions, anaphylactoid reactions or other manifestations of hypersensitivity. A course of action should therefore be planned in advance with necessary drugs and equipment available for immediate treatment, should a serious reaction occur. It is advisable always to use an indwelling cannula or catheter for quick intravenous access throughout the entire X-ray procedure.

Non-ionic contrast media have less effect on the coagulation system in vitro, compared to ionic contrast media. When performing vascular catheterization procedures one should pay meticulous attention to the angiographic technique and flush the catheter frequently (e.g.: with heparinised saline) so as to minimize the risk of procedure-related thrombosis and embolism.

Adequate hydration should be assured before and after contrast media administration. This applies especially to patients with multiple myeloma, diabetes mellitus, renal dysfunction, and elderly patients.

Care should also be taken in patients with serious cardiac disease and pulmonary hypertension as they may develop haemodynamic changes or

Encephalopathy has been reported with the use of iodixanol. Contrast encephalopathy may manifest with symptoms and signs of neurological dysfunction such as headache, visual disturbance, cortical blindness, confusion, seizures, loss of coordination, hemiparesis, aphasia, unconsciousness, coma and cerebral oedema within minutes to hours after administration of iodixanol, and generally resolves within days.

The product should be used with caution in patients with conditions that disrupt the integrity of the blood brain barrier (BBB), potentially leading to increased permeability of contrast media across the BBB and increasing the risk of encephalopathy.

Patients with acute cerebral pathology, tumours or a history of epilepsy are predisposed for seizures and merit particular care. Also alcoholics and drug addicts have an increased risk for seizures and neurological

In regard to intravascular application care should be taken in patients with acute stroke or acute intracranial bleeding, in patients with altered blood brain barrier, cerebral oedema or acute demyelination.

If contrast encephalopathy is suspected, administration of iodixanol should be discontinued and appropriate medical management should be initiated.

To prevent acute renal failure following contrast media administration, special care should be exercised in patients with pre-existing renal impairment and diabetes mellitus as they are at risk. Patients with paraproteinemias (myelomatosis and Waldenström's macroglobulinemia) are also at risk.

Preventive measures include:

- Identification of high risk patients
- Ensuring adequate hydration. If necessary by maintaining an i.v. infusion from before the procedure until the contrast medium has been cleared by the kidneys.
- Avoiding additional strain on the kidneys in the form of nephrotoxic drugs, oral cholecystographic agents, arterial clamping, renal arterial angioplasty, or major surgery, until the contrast medium has been cleared.
- Postponing a repeat contrast medium examination until renal function returns to pre-examination levels.

To prevent lactic acidosis, serum creatinine level should be measured in diabetic patients treated with metformin prior to intravascular administration of iodinated contrast medium. Normal serum creatinine/ renal function: Administration of metformin should be stopped at the time of administration of contrast medium and not resumed for 48 hours or until renal function/serum creatinine is normal. Abnormal serum creatinine/renal function: Metformin should be stopped and the contrast medium examination delayed for 48 hours. Metformin should only be restarted if renal function/serum creatinine is unchanged. In emergency cases where renal function is abnormal or unknown, the physician should evaluate the risk/benefit of the contrast medium examination, and precautions should be implemented: Metformin should be stopped, patient hydrated, renal function monitored and patient observed for symptoms of lactic acidosis.

Particular care is required in patients with severe disturbance of both renal and hepatic function as they may have significantly delayed contrast medium clearance. Patients on haemodialysis may receive contrast media for radiological procedures provided dialysis is performed immediately afterwards.

The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis. In patients with phaeochromocytoma undergoing interventional procedures, alpha blockers should be given as prophylaxis to avoid a hypertensive crisis. Special care should be exercised in patients with hyperthyroidism. Patients with multinodular goiter may be at risk of developing hyperthyroidism following injection of iodinated contrast media.

Extravasation of VISIPAQUE has not been reported, but it is likely that VISIPAQUE due to its isotonicity gives rise to less local pain and extravascular oedema than hyperosmolar contrast media. In case of extravasation, elevating and cooling the affected site is recommended as routine measures. Surgical decompression may be necessary in cases of compartment syndrome.

## Observation time

After contrast media administration the patient should be observed for at least 30 minutes, since the majority of side effects occurs within this time. However, experience shows that hypersensitivity reactions may appear up to several hours or days post injection.

# Interaction with other medicaments and other forms of interactions

Use of iodinated contrast media may result in a transient impairment of renal function and this may precipitate lactic acidosis in diabetics who are taking metformin (see section 4.4 Special warnings and special precautions for use).

Patients treated with interleukin-2 less than two weeks previous to an iodinated contrast medium injection have been associated with an increased risk for delayed reactions (flu-like symptoms or skin reactions).

All iodinated contrast media may interfere with tests on thyroid function, thus the iodine binding capacity of the thyroid may be reduced for up to several weeks.

High concentrations of contrast media in serum and urine can interfere with laboratory tests for bilirubin, proteins or inorganic substances (e.g. iron, copper, calcium and phosphate). These substances should therefore not be assayed on the day of examination.

### Pregnancy and lactation

The safety of VISIPAQUE for use in human pregnancy has not been established. An evaluation of experimental animal studies does not indicate direct or indirect harmful effects with respect to reproduction, development of the embryo or fetus, the course of gestation and peri- and postnatal development.

Since, wherever possible, radiation exposure should be avoided during pregnancy, the benefits of any X-ray examination, with or without contrast media, should be carefully weighed against the possible risk. The product should not be used in pregnancy unless benefit outweighs risk and it is considered essential by the physician.

The degree of excretion into human milk is not known, although expected to be low. Breast feeding should be discontinued prior to administration and should not be recommenced until at least 24 hours after the administration of VISIPAOUE.

Effects on ability to drive and use machines No effects are known.

#### Undesirable effects

Below are listed possible side effects in relation with radiographic procedures which include the use of VISIPAQUE.

#### Intravascular use:

Undesirable effects associated with the use of iodinated contrast media are usually mild to moderate and transient in nature, and less frequent with non-ionic than with ionic contrast media. Serious reactions as well as fatalities are only seen on very rare occasions.

The most frequent adverse event is a mild, general feeling of warmth or cold. Heat sensation in peripheral angiography is common (Incidence: >1:10), while distal pain occurs occasionally (Incidence < 1:10, but >1:100).

Abdominal discomfort/pain is very rare (Incidence < 1:1000) and gastrointestinal reactions like nausea or vomiting are rare (Incidence

Hypersensitivity reactions occur occasionally and usually present as mild respiratory or cutaneous symptoms like dyspnoea, rash, erythema, urticaria, pruritus and angioedema. They may appear either immediately after the injection or up to a few days later. Hypotension or fever may occur. Severe till toxic skin reactions have been reported. Severe manifestations such as laryngeal oedema, bronchospasm, pulmonary oedema and anaphylactic shock are very rare.

Anaphylactoid reactions may occur irrespectively of the dose and mode of administration and mild symptoms of hypersensitivity may represent the first signs of a serious reaction. Administration of the contrast medium must be discontinued immediately and, if necessary, specific therapy instituted via the vascular access. Patients using beta blockers may present with atypical symptoms of anaphylaxis which may be misinterpreted as a vagal reaction.

Vagal reactions giving hypotension and bradycardia are seen on very rare

lodism or "iodide mumps" is a very rare complication of iodinated contrast media resulting in swelling and tenderness of the salivary glands for up to approximately 10 days after the examination.

A minor transient increase in S-creatinine is common after iodinated contrast media, but usually of no clinical relevance. Renal failure is very rare. However, fatalities have been reported in high risk patient groups.

Arterial spasm may follow injection into coronary, cerebral or renal arteries and result in transient ischaemia.

Neurological reactions are very rare. They may include headache, dizziness, seizures or transient motor or sensory disturbances. On very rare occasions the contrast medium may cross the blood-brain barrier resulting in uptake of contrast medium in the cerebral cortex being visible on CT-scanning until the day following examination, sometimes associated with transient confusion or cortical blindness.

Cardiac complications are very rare, including arrhythmias, depression or signs of ischaemia. Hypertension may occur.

Post phlebographic thrombophlebitis or thrombosis is very rare. A very few cases of arthralgia have been reported.

Administration of the contrast medium must be discontinued immediately and, if necessary, specific therapy instituted via the vascular access. Patients using beta blockers may present with atypical symptoms of hypersensitivity which may be misinterpreted as a vagal reaction.

A minor transient increase in serum creatinine is common after iodinated contrast media but is usually of no clinical relevance.

The frequencies of undesirable effects are defined as follows: Very common (≥1/10), common (≥1/100 to <1/10) uncommon (>1/1 000 to <1/100) rare (>1/10 000 to <1/1 000) very rare (<1/10.000) and not known (cannot be estimated from the

available data).

The listed frequencies are based on internal clinical documentation and published studies, comprising more than 57,705 patients.

#### Intravascular administration:

Blood and lymphatic system disorders Not known: Thrombocytopenia Immune system disorders: Uncommon: Hypersensitivity Not known: Anaphylactic/anaphylactoid shock, anaphylactic/anaphylactoid reaction including life-threatening or fatal anaphylaxis

Endocrine disorders: Not known: Hyperthyroidism, hypothyroidism Psychiatric disorders:

Very rare: Agitation anxiety Not known: Confusional state

# Nervous system disorders:

Rare: Dizziness, sensory abnormalities including dysgeusia, paraesthesia, parosmia

Very rare: Cerebrovascular accident, amnesia. syncope, tremor (transient), hypogesthesia

Not known: Coma. disturbance in consciousness, convulsion, transient contrast-induced encephalopathy\* caused by extravasation of contrast media, which can manifest as sensory, motor or global neurological

\* See Description of selected adverse reactions for more details.

#### Eve disorders:

Very rare: Cortical blindness (transient), visual impairment (including diplopia, blurred vision), eyelid oedema

#### Cardiac disorders:

Rare: Arrhythmia (including bradycardia, tachycardia), myocardial infarction

Very rare: Cardiac arrest, palpitations

Not known: Cardiac failure, ventricular hypokinesia, spasms of coronary

cardio-respiratory arrest, conduction abnormalities, coronary artery thrombosis, anging pectoris

Vascular disorders: Uncommon: Flushing Rare: Hypotension Very rare: Hypertension, ischaemia

Not known: Shock, arterial spasm, thrombosis, thrombophlebitis

Respiratory, thoracic and mediastinal disorders: Rare: Cough, sneezing Very rare: Dyspnoea, throat irritation, laryngeal oedema Not known: Non-cardiogenic pulmonary oedema, respiratory arrest,

respiratory failure, bronchospasm, throat tightness, pharyngeal oedema

#### Gastrointestinal disorders:

Uncommon: Nausea, vomitina Very rare: Abdominal pain/discomfort, diarrhoea

Not known: Acute pancreatitis, pancreatitis aggravated, salivary gland enlaraement

#### Skin and subcutaneous system disorders Uncommon: Rash or drug eruption, pruritus, urticaria

Very rare: Angioedema, erythema, hyperhidrosis Not known: Bullous or exfoliative dermatitis, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, acute generalised exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms

Musculoskeletal and connective tissue disorders: Very rare: Back pain, muscle spasm Not known: Arthralgia

Renal and urinary disorders: Uncommon: Acute kidney injury or nephropathy toxic (contrast induced nephropathy-CIN) Not known: Increased blood creatinine

General disorders and administration site conditions:

Uncommon: chest pain, feeling of body temperature change Rare: Shivering (chills), pyrexia, pain and discomfort, administration site reactions including extravasation

Very rare: Asthenic conditions (e.g. malaise, fatigue), face oedema, localised oedema

Not known: Swelling Injury, poisoning and procedural complications: Not known: Iodism

#### Description of selected adverse reactions:

Transient contrast-induced encephalopathy: In unknown occasions the contrast medium may cross the blood-brain barrier resulting in uptake of contrast medium in the cerebral cortex that may cause contrast-induced encephalopathy. The symptoms may include agitation, transient cortical blindness, amnesia, hallucination, paralysis, paresis, disorientation, transient speech disorder, aphasia, dysarthria.

# Overdose

Overdosage is unlikely in patients with a normal renal function. The duration of the procedure is important for the renal tolerability of high doses of contrast media ( $t_{\frac{1}{2}} \sim 2$  hours). In the event of accidental overdosing, the water and electrolyte losses must be compensated by infusion. Renal function should be monitored for at least the next 3 days. If needed, haemodialysis may be used to remove iodixanol from the patient's system. There is no specific antidote.

#### PHARMACOLOGICAL PROPERTIES

# Pharmacodynamic properties

The organically bound iodine absorbs radiation in the blood vessels/tissues when it is injected. For most of the haemodynamic, clinical-chemical and coagulation parameters examined following intravenous injection of iodixanol in healthy volunteers, no significant deviation from preiniection values has been found. The few changes observed in the laboratory parameters were minor and considered to be of no clinical importance.

VISIPAQUE induces only minor effects on renal function in patients. In diabetic patients with serum creatinine levels of 1.3-3.5 mg/dl, VISIPAQUE use resulted in 3% of patients experiencing a rise in creatinine of  $\geq 0.5$ ma/dl and 0% of the patients with a rise of  $\geq$  1.0 ma/dl. The release of enzymes (alkaline phosphatase and N-acetyl-B-glucosaminidase) from the proximal tubular cells is less than after injections of non-ionic monomeric contrast media and the same trend is seen compared to ionic dimeric contrast media. VISIPAQUE is also well tolerated by the kidney.

Cardiovascular parameters such as LVEDP, LVSP, heart rate and QT-time as well as femoral blood flow were less influenced after VISIPAQUE than after other contrast media, where measured.

# Pharmacokinetic properties

lodixanol is rapidly distributed in the body with a mean distribution halflife of approximately 21 minutes. The apparent volume of distribution is of the same magnitude as the extracellular fluid (0.26 l/kg b.w.), indicating that iodixanol is distributed in the extra-cellular volume only.

No metabolites have been detected. The protein binding is less than 2%.

The mean elimination half-life is approximately 2 hours. Iodixanol is excreted mainly through the kidneys by glomerular filtration. Approximately 80% of the administered dose is recovered un-metabolized in the urine within 4 hours and 97% within 24 hours after intravenous injection in healthy volunteers. Only about 1.2% of the injected dose is excreted in faeces within 72 hours.

The maximum urinary concentration appears within approximately 1 hour after injection.

No dose dependent kinetics have been observed in the recommended dose range.

#### Preclinical safety data

Reproduction studies in rats and rabbits have revealed no evidence of impaired fertility or teratogenicity due to iodixanol.

# PHARMACEUTICAL PARTICULARS

# List of excipients

The following excipients are included: Trometamol, sodium chloride, calcium chloride dihydrate, sodium calcium edetate, hydrochloric acid (pH adjustment) and water for injections. The pH of the product is 6.8 - 7.6.

# Incompatibilities

No incompatibility has been found. However, VISIPAQUE should not be directly mixed with other drugs. A separate syringe should be used.





### Shelf life

The expiry date is stated on the label.

# Special precautions for storage

VISIPAQUE should be stored at up to 30°C protected from light. The product in glass containers and in 40, 50, 75, 100, 150, 175, 200 and 500 ml polypropylene bottles may be stored at 37°C for up to 1 month prior to use. 10 and 20 ml polypropylene bottles may be stored at 37°C for up to 1 month prior to use. up to 1 week prior to use.

# Nature and content of container

Glass vials and bottles:

The product is filled in injection vials (20 ml) and infusion bottles (50, 75, 100, 200 and 500 ml). Both containers are made of colourless highly resistant borosilicate glass (Ph.Eur. Type I), closed with halobutyl rubber stoppers (Ph.Eur. Type I), and sealed with complete tear off caps with coloured plastic "flip-off" tops.

# Polypropylene bottles:

The product is filled in polypropylene bottles. The bottles of 10, 20, 40 and 50 ml are rigid stand-up bottles with a twist-off top.

The bottles of 50, 75, 100, 150, 175, 200 and 500 ml are supplied with a plastic screw cap which is provided with a tamper proof ring.

The product is supplied as:

# Glass vials/bottles

Class Vials, beccies	
270 mg I/ml:	10 vials of 20ml
	10 bottles of 50ml
	10 bottles of 100ml
	6 bottles of 200ml
	6 bottles of 500ml
320 mg I/ml:	10 vials of 20ml
•	10 bottles of 50ml
	10 bottles of 100ml
	6 bottles of 200ml
	6 bottles of 500ml

	10 bottles of 100ml	
	6 bottles of 200ml	
	6 bottles of 500ml	
Polypropylene bottles:		
270 mg I/ml:	10 bottles of 10ml	
	10 bottles of 20ml	
	10 bottles of 40ml	
	10 bottles of 50ml	
	10 bottles of 75ml	
	10 bottles of 100ml	
	10 bottles of 150ml	
	10 bottles of 175ml	
	10 bottles of 200ml	
	6 bottles of 500ml	
320 mg I/ml	10 bottles of 10ml	
•	10 bottles of 20ml	
	10 bottles of 40ml	
	10 bottles of 50ml	
	10 bottles of 75ml	
	10 bottles of 100ml	
	10 bottles of 150ml	
	10 bottles of 175ml	

In certain countries some package sizes may not be available.

10 bottles of 200ml 6 bottles of 500ml

# **INSTRUCTIONS FOR USE/HANDLING**

Like all parenteral products, VISIPAQUE should be inspected visually for particulate matter, discolouration and the integrity of the container prior to use. Not to be used if it is discoloured or contains a

The product should be drawn into the syringe immediately before use. Vials are intended for single use only, any unused portions must be discarded. VISIPAQUE may be warmed to body temperature (37°C) before administration.

### ADDITIONAL INSTRUCTION FOR AUTO INJECTOR/PUMP

The 500 ml contrast medium bottles should only be used in connection with auto injectors/pumps approved for this volume. A single piercing should be used.

The line running from the auto injector/pump to the patient must be exchanged after each patient. Any unused portions of the contrast medium remaining in the bottle and all connecting tubes must be discarded at the end of the day. When convenient, smaller bottles can also be used. Instructions from the manufacturer of the auto injector/ pump must be followed.

### DATE OF REVISION OF THE TEXT

December 2020

Visipaque is a trademark of GE Healthcare. GE and the GE Monogram are trademarks of General Electric Company.

#### Manufactured in China by:

GE Healthcare (Shanghai) Co., Ltd. No. 1, Niudun Road China (Shanghai) Pilot Free Trade Zone Shanghai-201203, China

### Manufactured in Ireland by:

GE Healthcare Ireland Ltd. IDA Business Park, Carrigtohill Co. Cork, Ireland

### Manufactured in Norway by:

GE Healthcare AS Nycoveien 1. NO-0485 Oslo, Norway

### WARNING

To be sold by retail on prescription of a Registered Medical Practitioner only.



